Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Aralez to acquire U.S. rights to Toprol-XL from AstraZeneca

Oct. 5, 2016

EUCLID trial of Brilinta in peripheral artery disease does not meet primary endpoint

Oct. 4, 2016

Oncodesign discloses ALK-1 and/or ALK-2 inhibitors

Oct. 4, 2016

Aralez Pharmaceuticals announces availability of Yosprala antiplatelet therapy

Oct. 4, 2016

Micatrio approved in Japan for hypertension

Oct. 3, 2016

Amgen and Arrowhead Pharmaceuticals sign cardiovascular license and collaboration agreements

Sep. 30, 2016

DoD grant supports cardiac cell therapy trial in HFpEF

Sep. 29, 2016

Enrollment opens in phase III VICTORIA study of vericiguat for HFrEF

Sep. 28, 2016

Inotrem completes phase I study of Motrem

Sep. 16, 2016

FDA approves Aralez Pharmaceuticals' Yosprala

Sep. 16, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....